Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 19, 2020

IMV to progress clinical development of Covid-19 vaccine

IMV has initiated plans to progress the clinical development of a Covid-19 vaccine candidate. The aim is to determine the clinical safety and immunogenicity.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

IMV has initiated plans to progress the clinical development of a Covid-19 vaccine candidate, to determine the clinical safety and immunogenicity.

Based on the company’s DPX delivery technology, the vaccine candidate DPX-COVID-19 comprises peptides that target epitopes from the novel coronavirus strain.

The peptide-based approach, along with the DPX platform, speeds up the development and production of a vaccine.

IMV plans to advance its vaccine candidate into Phase I clinical trial.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

IMV CEO Frederic Ors said: “Across our many clinical studies, we have observed DPX technology to elicit a robust immune response with a sustained effect, including in sensitive populations.

“We believe this technology offers a meaningful solution as a potential vaccine, especially in older adults and those with pre-existing conditions who are most at risk to this virus and generally more difficult to vaccinate effectively.”

The company’s Covid-19 vaccine candidate is being designed based on third-party immunological SARS-CoV studies and SARS-CoV-2 sequencing data.

Related Companies

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU